Table 2.
Experimental groups | ALT | AST | ALP | γ-GT |
---|---|---|---|---|
(U/g) | (U/g) | (U/g) | (U/g) | |
Control | 304 ± 1.8 | 229 ± 1.8 | 16 ± 1 | 25 ± 0.8 |
PZQ | 315 ± 1.7a | 220 ± 4.5a | 13 ± 0.3a | 18 ± 1a |
BER | 318 ± 1.4a | 255 ± 2.3a | 7.4 ± 0.4a | 15 ± 0.8a |
Infected | 218 ± 3.6a | 125 ± 1a | 36 ± 1.2a | 48 ± 1.6a |
Infected + PZQ | 263 ± 1.3abc | 146 ± 1.9 abc | 17 ± 1bc | 16 ± 0.5ac |
Infected + BER | 280 ± 2.8abc | 182 ± 2.4abc | 12 ± 1.6abc | 20 ± 0.6abc |
Values are means ± SD (n = 8). aSignificant difference as compared with Group I (p ≤ 0.05). bSignificant difference as compared with corresponding control group (p ≤ 0.05). cSignificant difference as compared with infected group (Group IV) (p ≤ 0.05).